ArticleAnnals of surgical oncology2026
Clinical Machine Learning Model for Predicting Pathological Complete Response in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma After Trimodality Therapy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate prediction of pathological complete response (pCR) after preoperative chemoradiation therapy, followed by surgery (trimodality therapy) in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC) may improve clinical decision-making and patient counseling before esophagectomy. This study aimed to develop predictive models for pCR after trimodality using machine learning (ML) approaches. PATIENTS AND
methodsA total of 569 patients with EAC and GEJAC who received trimodality therapy at MD Anderson Cancer Center between 2002 and 2022 were included. Clinicopathological characteristics and survival benefit of patients who achieved a pCR were reviewed via descriptive and survival analyses. Subsequently, ML models based on clinical variables were employed to predict pCR, including BART, random forest, and XGBoost, logistic regression, and LASSO.
resultspCR was achieved in 132 patients (23.2%). Poorly differentiated tumors, tumors with signet ring cell component, higher T stage, higher clinical stage, residual tumor on biopsy after chemoradiation, and higher SUVmax on positron emission tomography-contract tomography (PET-CT) after chemoradiation were significantly associated with non-pCR. pCR patients had significantly longer overall survival (OS) and relapse free survival (RFS) compared with non-pCR patients (median OS, 10.40 versus 4.42 years, log-rank p = 0.0041; median RFS, 10.40 versus 2.35 years, log-rank p < 0.0001). The random forest model showed the highest predictive ability for pCR with an AUC value of 0.702 among the employed models.
conclusionsThis first exploratory study supports the validity and potential utility of ML-based models for predicting pCR after trimodality therapy in EAC and GEJAC. Further validation is warranted before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.